Tryp Therapeutics Past Earnings Performance
Past criteria checks 0/6
Tryp Therapeutics has been growing earnings at an average annual rate of 4.9%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually.
Key information
4.9%
Earnings growth rate
56.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Tryp Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 0 | -3 | 2 | -1 |
| 30 Nov 23 | 0 | -5 | 2 | 2 |
| 31 Aug 23 | 0 | -5 | 2 | 2 |
| 31 May 23 | 0 | -6 | 2 | 4 |
| 28 Feb 23 | 0 | -6 | 2 | 4 |
| 30 Nov 22 | 0 | -6 | 3 | 3 |
| 31 Aug 22 | 0 | -7 | 4 | 3 |
| 31 May 22 | 0 | -8 | 6 | 2 |
| 28 Feb 22 | 0 | -10 | 8 | 2 |
| 30 Nov 21 | 0 | -11 | 8 | 2 |
| 31 Aug 21 | 0 | -8 | 6 | 1 |
| 31 May 21 | 0 | -6 | 5 | 0 |
Quality Earnings: TRYP is currently unprofitable.
Growing Profit Margin: TRYP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRYP is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare TRYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRYP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: TRYP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.